Bristol-Myers Squibb (BASE:BMY) - Prezzo delle azioni, notizie e analisi

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

BMY Panoramica delle azioni

Bristol-Myers Squibb Company scopre, sviluppa, concede in licenza, produce, commercializza, distribuisce e vende prodotti biofarmaceutici in tutto il mondo.

Informazioni sull'azienda

BMY analisi fondamentale
Punteggio fiocco di neve
Valutazione	4/6
Crescita futura	4/6
Prestazioni passate	0/6
Salute finanziaria	3/6
Dividendi	5/6

Premi

Negoziato a 58.3% al di sotto della nostra stima del suo valore equo

Si prevede che gli utili cresceranno del 45.95% all'anno

Analisi del rischio

Ha un alto livello di debito

Il dividendo di 4.87% non è ben coperto dagli utili

Bristol-Myers Squibb Company Concorrenti

Zoetis

NYSE:ZTS

US$88.3b

GSK

LSE:GSK

UK£62.7b

Chugai Pharmaceutical

TSE:4519

JP¥12.1t

Merck KGaA

XTRA:MRK

€69.8b

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Bristol-Myers Squibb
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$20,900.00
Massimo di 52 settimane	US$22,500.00
Minimo di 52 settimane	US$12,999.00
Beta	0.46
1Variazione di 1 mese	-3.46%
Variazione a 3 mesi	7.33%
Variazione di 1 anno	31.53%
3Variazione a 3 anni	445.69%
Variazione a 5 anni	2,275.02%
Variazione dall'IPO	79,267.88%

Notizie e aggiornamenti recenti

Recent updates

Rendimenti per gli azionisti

	BMY	AR Pharmaceuticals	AR Mercato
7D	3.6%	-0.07%	-4.9%
1Y	31.5%	-13.9%	176.0%

Ritorno vs Industria: BMY ha superato il AR Pharmaceuticals che ha restituito -11.7 % nell'ultimo anno.

Rendimento vs Mercato: BMY ha avuto una performance inferiore al mercato AR che ha registrato un rendimento 166.6 % nell'ultimo anno.

Volatilità dei prezzi

Is BMY's price volatile compared to industry and market?
BMY volatility
BMY Average Weekly Movement	6.1%
Pharmaceuticals Industry Average Movement	6.1%
Market Average Movement	7.0%
10% most volatile stocks in AR Market	8.6%
10% least volatile stocks in AR Market	4.9%

Prezzo delle azioni stabile: BMY non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 7% ) di BMY è rimasta stabile nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
1887	34,100	Chris Boerner	www.bms.com

Bristol-Myers Squibb Company scopre, sviluppa, concede in licenza, produce, commercializza, distribuisce e vende prodotti biofarmaceutici in tutto il mondo. Offre prodotti per malattie ematologiche, oncologiche, cardiovascolari, immunologiche, fibrotiche e neuroscientifiche. I prodotti dell'azienda includono Eliquis per la riduzione del rischio di ictus/embolia sistemica nella fibrillazione atriale non valvolare e per il trattamento di TVP/PE; Opdivo per varie indicazioni antitumorali, tra cui il cancro della vescica, del sangue, del CRC, della testa e del collo, RCC, HCC, del polmone, del melanoma, MPM, dello stomaco e dell'esofago; Pomalyst/Imnovid per il mieloma multiplo; Orencia per l'artrite reumatoide attiva e l'artrite psoriasica; e Sprycel per il trattamento della leucemia mieloide cronica positiva al cromosoma Philadelphia.

Bristol-Myers Squibb Company Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Bristol-Myers Squibb con la sua capitalizzazione di mercato?
BMY statistiche fondamentali
Capitalizzazione di mercato	AR$99.76t
Guadagni(TTM)	-AR$6.32t
Ricavi(TTM)	AR$44.95t

2.2x

Rapporto P/S

-15.8x

Rapporto P/E

BMY è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
BMY Conto economico (TTM)
Ricavi	US$46.51b
Costo del fatturato	US$11.08b
Profitto lordo	US$35.43b
Altre spese	US$41.97b
Guadagni	-US$6.54b

Ultimi guadagni dichiarati

Jun 30, 2024

Prossima data di guadagno

Oct 31, 2024

Utile per azione (EPS)	-3.23
Margine lordo	76.18%
Margine di profitto netto	-14.06%
Rapporto debito/patrimonio netto	306.9%

Come si è comportato BMY nel lungo periodo?

Vedi performance storica e confronto

Dividendi

4.7%

Rendimento attuale del dividendo

-74%

Rapporto di remunerazione

BMY paga dividendi affidabili?

Vedere la storia dei dividendi e i benchmark di BMY

Quando è necessario acquistare BMY per ricevere un dividendo imminente?
Bristol-Myers Squibb date dei dividendi
Data di stacco del dividendo	Oct 04 2024
Data di pagamento dei dividendi	Nov 01 2024
Giorni fino al dividendo Ex	4 days
Giorni prima della data di pagamento dei dividendi	32 days

BMY paga dividendi affidabili?

Vedere la storia dei dividendi e i benchmark di BMY

BMY Panoramica delle azioni

Premi

Analisi del rischio

Bristol-Myers Squibb Company Concorrenti

NYSE:ZTS

US$88.3b

LSE:GSK

UK£62.7b

TSE:4519

JP¥12.1t

XTRA:MRK

€69.8b

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Bristol Myers Squibb Presents New Data from Two Trials Demonstrating Sotyktu (Deucravacitinib) Efficacy in Both Moderate-To-Severe Scalp Psoriasis and in A Real-World Setting

U.S. Food and Drug Administration Approves Bristol Myers Squibb's COBENFY (xanomeline and Trospium Chlorx), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults

Bristol Myers Squibb Announces New Long-Term Zeposia (ozanimod) Data Demonstrate Durable Efficacy and Consistent Safety in Relapsing Forms of Multiple Sclerosis

Bristol Myers Squibb Presents Landmark 10-Year Follow-Up Data from Checkmate -067 Which Showed Continued Durable Long-Term Survival Benefit with Opdivo® Plus Yervoy® in Advanced Melanoma

Bristol-Myers Squibb Company to Report Q3, 2024 Results on Oct 31, 2024

Bristol Myers Squibb Announces Long-Term Follow-Up Data from Phase 3 Study of CAMZYOS (Mavacamten) Underscores Established Efficacy and Safety Profile in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

Recent updates

Bristol Myers Squibb Presents New Data from Two Trials Demonstrating Sotyktu (Deucravacitinib) Efficacy in Both Moderate-To-Severe Scalp Psoriasis and in A Real-World Setting

U.S. Food and Drug Administration Approves Bristol Myers Squibb's COBENFY (xanomeline and Trospium Chlorx), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults

Bristol Myers Squibb Announces New Long-Term Zeposia (ozanimod) Data Demonstrate Durable Efficacy and Consistent Safety in Relapsing Forms of Multiple Sclerosis

Bristol Myers Squibb Presents Landmark 10-Year Follow-Up Data from Checkmate -067 Which Showed Continued Durable Long-Term Survival Benefit with Opdivo® Plus Yervoy® in Advanced Melanoma

Bristol-Myers Squibb Company to Report Q3, 2024 Results on Oct 31, 2024

Bristol Myers Squibb Announces Long-Term Follow-Up Data from Phase 3 Study of CAMZYOS (Mavacamten) Underscores Established Efficacy and Safety Profile in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

Bristol Myers Squibb Receives U.S. Food and Drug Administration sBLA Acceptance for First-Line Treatment of Unresectable Hepatocellular Carcinoma

European Medicines Agency Validates Bristol Myers Squibb's Application for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma

Bristol-Myers Squibb Company Announces Intangible Asset Impairment Charges for the Three Months Ended June 30, 2024

Bristol Myers Squibb Receives European Medicines Agency Validation of Application for Opdivo (Nivolumab) Plus Yervoy (Ipilimumab) for First-Line Treatment of Unresectable or Advanced Hepatocellular Carcinoma

Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI®? (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)

Bristol-Myers Squibb Company to Report Q2, 2024 Results on Jul 26, 2024

Bristol Myers Squibb Appoints Michael R. McMullen as Independent Director and Member of the Audit Committee, Effective July 1, 2024

Bristol Myers Squibb Declares A Quarterly Dividend, Payable on August 1, 2024

Bristol Myers Squibb Announces Opdivo (Nivolumab) Plus Yervoy (Ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carinoma in Checkmate -9DW Trial

Bristol Myers Squibb’S Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented At 2024 Asco® Annual Meeting

U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma

Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) in Combination with Cisplatin and Gemcitabine

Bristol Myers Squibb Announces New Four-Year Results from the POETYK PSO Long-Term Extension Trial of Sotyktu (Deucravacitinib) Treatment in Adult Patients with Moderate-To-Severe Plaque Psoriasis

Bristol Myers Squibb's CAR T Cell Therapy Breyanzi Approves by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma

Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial

U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase)

European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer

CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb's Opdivo (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma

Bristol Myers Squibb Announces KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)

U.S. Fda Approves Bristol Myers Squibb and 2Seventy Bio’S Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy

European Commission Expands Approval of Bristol Myers Squibb’S Reblozyl® (Luspatercept)

Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (Oozanimod) in Patients with Moderate to Severe Active Crohn's Disease

Bristol Myers Squibb to Present Data at the American College of Cardiology Annual Scientific Session 2024

Bristol Myers Squibb’s Abecma (idecabtagene vicleucel) Becomes First CAR T Cell Therapy Approved in the European Union in Earlier Lines for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma

Bristol-Myers Squibb Company, Annual General Meeting, May 07, 2024

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of Karuna Therapeutics, Inc. (NasdaqGM:KRTX) from Capital International Investors, FMR LLC, The Vanguard Group, Inc., T. Rowe Price Group, Inc. (NasdaqGS:TROW) and others.

FDA Advisory Committee Votes in Favor of Bristol-Myers Squibb Company and 2seventy bio, Inc. Abecma for Triple-Class Exposed Multiple Myeloma in Further Lines of Therapy

U.S. FDA Approves Bristol Myers Squibb’s Breyanzi® as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Bristol-Myers Squibb Company to Report Q1, 2024 Results on Apr 25, 2024

U.S. Food and Drug Administration Approves Bristol-Myers Squibb Company's Opdivo

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of RayzeBio, Inc. (NasdaqGM:RYZB).

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of RayzeBio, Inc. (NasdaqGM:RYZB).

Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl® (luspatercept) for Treatment of Adults with Transfusion-Dependent Anemia due to Low- to Intermediate-Risk Myelodysplastic Syndromes (MDS)

Bristol-Myers Squibb Company Announces Management Changes

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Augtyro (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors

Bristol Myers Squibb Announces Acceptance of U.S. and EU Regulatory Filings for Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo in Resectable Non-Small Cell Lung Cancer

Bristol Myers Squibb and 2seventy bio, Inc. Share Update on U.S. FDA Oncologic Drugs Advisory Committee Meeting for Abecma in Triple-Class Exposed Multiple Myeloma Based on KarMMa-3 Study

Bristol-Myers Squibb Company Announces Three Regulatory Acceptances from the U.S. Food and Drug Administration (FDA) and Japan’S Ministry of Health, Labour and Welfare (MHLW) for Breyanzi

Bristol Myers Squibb Announces the First Disclosure of Data from the Phase 3 CheckMate -67T Trial

Bristol-Myers Squibb Company Receives Positive Chmp Opinion for Car T Cell Therapy Abecma (Idecabtagene Vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma

Bristol Myers Squibb and Exelixis, Inc. Announce Four-Year Follow-Up Results from the CheckMate -9ER Trial Evaluating Opdivo (cabozantinib)

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of Mirati Therapeutics, Inc. (NasdaqGS:MRTX) from a group of shareholders.

Bristol Myers Squibb Announces Results from the Phase 3 Randomized Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab)

Bristol Myers Squibb Data At Asco Gu 2024 Showcase Transformative Research in the Treatment of Genitourinary Cancers

European Medicines Agency Validates Bristol Bristol-Myers Squibb Company Application for Repotrectinib for the Treatment of Locally Advanced or Metastatic Ros1-Positive Non-Small Cell Lung Cancer and Ntrk-Positive Solid Tumors

Bristol-Myers Squibb Company (NYSE:BMY) entered into definitive merger agreement to acquire RayzeBio, Inc. (NasdaqGM:RYZB) for $3.8 billion.

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive merger agreement to acquire Karuna Therapeutics, Inc. (NasdaqGM:KRTX) for $12.6 billion.

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive merger agreement to acquire Karuna Therapeutics, Inc. (NasdaqGM:KRTX) for $12.5 billion.

Bristol-Myers Squibb Company to Report Q4, 2023 Results on Feb 02, 2024

Bristol Myers Squibb and 2seventy bio, Inc. Announce Results from the Preplanned Final Progression-Free Survival Analysis of KarMMa-3

Bristol Myers Squibb Presents Primary Efficacy and Safety Analysis of the Phase 3 Commands Trial of Reblozyl for Treatment of Anemia in Erythropoiesis Stimulating Agent-Naïve Patients with Lower-Risk Myelodysplastic Syndromes At Ash 2023

Rendimenti per gli azionisti

Volatilità dei prezzi